CLOs on the Move

Elevance Health

www.elevancehealth.com

 
Fueled by our bold purpose to improve the health of humanity, we are transforming from a traditional health benefits organization into a lifetime trusted health partner.   Our nearly 100,000 associates serve more than 118 million people, at every stage of health. We address a full range of needs with an integrated whole health approach, powered by industry-leading capabilities and a digital platform for health.  We believe that improving health for everyone is possible. It begins by redefining health, reimagining the health system, and strengthening our communities.
  • Number of Employees: 10K-50K
  • Annual Revenue: > $1 Billion

Executives

Name Title Contact Details
Marc Linden
Senior Legal Counsel Profile
Miriam Goganious
Vice President Compliance Program Administration Profile
Travis Walker
Regional Vice President, Benefits Compliance Profile
Todd Simpson
Chief Information Officer Profile
Kevin Olson
Sr Associate General Counsel Profile

Similar Companies

Lutheran Home Care and Hospice

Lutheran Home Care & Hospice is a Chambersburg, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Dermatology Professionals

Dermatology Professionals is a Baxter, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Avecia

Avecia is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. Avecia is based in Milford, MA. You can find more information on Avecia at www.avecia.com

Neuralstem

Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic

Northwestern Community Services Board

Northwestern Community Services Board is a public mental health provider that offers an array of outpatient, case management, day support, residential and emergency programs that are designed to enhance the quality of life for both children and adults ...